

SUPPLEMENTARY DATA

Supplementary Table 1. Comparison of second cohort of RYGB subjects prior to and three months after intervention during OGTT.

AUC: area under the curve; EX9: exendin₉₋₃₉; HOMA-IR: homeostatic model assessment-insulin ISI: insulin sensitivity index; O-ICR: insulin clearance rate after oral glucose; O-ISR: insulin secretion rate after oral glucose; RYGB: Roux-en-Y gastric bypass; Sal: saline; T2DM: type 2 diabetes mellitus. Mean \pm SD. * p <0.05 for paired t-test vs. pre-RYGB; † p <0.05 for paired t-test vs. saline condition.

	Pre-RYGB	3 months + Sal	3 months + EX9
Age (y)	44.1 \pm 8.6		
Gender (% female)	91%		
Known T2DM duration (y)	8.26 \pm 7.64		
HbA1c (%)	7.89 \pm 1.15	6.30 \pm 0.87*	
HbA1c (mmol/mol)	62.8 \pm 0.1	45.3 \pm 0.08*	
Weight (kg)	110 \pm 18.0	91.1 \pm 15.2*	
BMI (kg/m²)	42.1 \pm 5.1	34.9 \pm 4.6*	
Weight loss (%)	-	17.1 \pm 3.52	
Oral T2DM medication use (# of subjects)	20/22	4/22	
Insulin Use (# subjects)	9/22	2/22	
Fasting insulin (pmol/L)	248 \pm 147	98.8 \pm 53.5*	
Fasting glucose (mmol/L)	7.73 \pm 2.38	5.80 \pm 1.00*	
120' glucose (mmol/L)	10.7 \pm 3.2	9.29 \pm 3.13*	
HOMA-IR	12.1 \pm 7.77	3.79 \pm 2.50*	
ISI	1.78 \pm 1.26	3.25 \pm 1.68*	
O-ISR AUC (pmol/kg)	710 \pm 482	1006 \pm 621*	514 \pm 411*†
Insulin levels AUC (nmol/L*min)	112 \pm 135	113 \pm 134	55.2 \pm 66.7†
O-ICR (mL/kg/min)	8.45 \pm 4.24	11.3 \pm 3.82*	13.9 \pm 6.94*†